Status:
COMPLETED
Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction
Lead Sponsor:
Mesoblast, Inc.
Conditions:
Myocardial Infarction
Eligibility:
All Genders
21-85 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to determine whether adult stem cells \[Provacel™(PUMP1)\] are safe and possibly effective in the treatment of acute myocardial infarction (heart attack).
Detailed Description
Cardiovascular disease is the single largest killer of males and females in the United States with an average of 335,000 deaths per year. This year an estimated 700,000 Americans will suffer an acute ...
Eligibility Criteria
Inclusion
- Male or female between 21 and 85 years old
- First heart attack within 1 to 10 days
Exclusion
- Positive for HIV 1 and 2
- Previous heart attack
- Pacemaker or other device
- Pregnant or breastfeeding
- Allergic to cow or pig derived products
- Previous bone marrow transplant
- Involved in another clinical trial within the past 30 days
- Alcohol or recreational drug abuse within the past 6 months
- Hepatitis Positive
- Major surgical procedure or major trauma within the past 14 days
- Body weight greater than 300 pounds
- Autoimmune disease ( e.g. Lupus, Multiple Sclerosis)
Key Trial Info
Start Date :
March 22 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 24 2008
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00114452
Start Date
March 22 2005
End Date
April 24 2008
Last Update
March 10 2020
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Heart Institute
Phoenix, Arizona, United States, 85006
2
University of California - San Diego; Thornton
San Diego, California, United States, 92103-8411
3
Washington Hospital Center
Washington D.C., District of Columbia, United States, 20010
4
Rush University Medical Center
Chicago, Illinois, United States, 60612